Company Overview
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -28.60% |
| 6 Months: | -28.17% |
| 3 Months: | +19.27% |
| 1 Month: | +15.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)49.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 34.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EIKN Eikon Therapeutics, Inc. PHARMA | 10.71 | -1.80 | $580.11M | 0.00% | -42.07% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 67.78M | 71.38M | 83.17M | 87.34M |
| Operating Income | -67.78M | -71.38M | -83.17M | -87.34M |
| EBITDA | -58.70M | -64.92M | -74.60M | -82.22M |
| Interest Expense | 7.00K | - | -48.00K | - |
| Pretax Income | -64.92M | -68.24M | -79.66M | -82.96M |
| Tax Provision | - | - | - | - |
| Net Income | -64.92M | -68.24M | -79.66M | -82.96M |
| Diluted EPS | - | -2.28 | - | -2.46 |
| R&D Expense | - | 56.59M | - | 70.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 265.74M | 260.34M | 338.94M |
| Operating Income | -265.74M | -260.34M | -338.94M |
| EBITDA | -224.21M | -218.39M | -299.24M |
| Interest Expense | 39.00K | 31.00K | 837.00K |
| Pretax Income | -242.00M | -243.81M | -324.25M |
| Tax Provision | - | - | - |
| Net Income | -242.00M | -243.81M | -324.25M |
| Diluted EPS | -7.40 | -7.45 | -6.18 |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -190.85M | -134.80M | -188.52M |
| Investing Cash Flow | 136.95M | 151.35M | -181.34M |
| Financing Cash Flow | 105.81M | 244.00K | 352.05M |
| Capital Expenditure | -28.51M | -84.80M | -46.74M |
| Free Cash Flow | -219.36M | -219.60M | -235.26M |
| Net Change in Cash | 51.91M | 16.80M | -17.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 9.22% | 4.99M | $44.70M |
| 2 | Blackrock Inc. | 7.90% | 4.28M | $38.32M |
| 3 | Foresite Capital Management IV, LLC | 3.59% | 1.94M | $17.40M |
| 4 | Merck & Co., Inc. | 3.08% | 1.67M | $14.92M |
| 5 | T. Rowe Price Investment Management, Inc. | 2.95% | 1.60M | $14.28M |
| 6 | Foresite Capital Management V, LLC | 2.44% | 1.32M | $11.80M |
| 7 | Capital World Investors | 2.17% | 1.18M | $10.52M |
| 8 | Price (T.Rowe) Associates Inc | 1.86% | 1.01M | $9.00M |
| 9 | Vanguard Capital Management LLC | 1.70% | 922.71K | $8.26M |
| 10 | EcoR1 Capital, LLC | 1.35% | 732.61K | $6.56M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EIKN
Insider Purchase: 10% owner at $EIKN Buys 89,200 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPbHBvdEQ3dU1KNW5tNG8wUlhrWDZtQk1iZFNRSk1NR0F3a1h1NUJrUmh4UUh5ZHVLTzVMLUJTQk1uWm1QOTdsRHA2SVR6dHg4WVBHZERyMnpZOWZJQVYzb3B0a3RGcWltckpvZnlyU1BTX0NrUjdSWHhjeGhfTngzN3VQRndybUtiaHFzVn…
Open-market insider buy at Eikon Therapeutics (EIKN) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOS3dYZllvTDdCSDJVSUkyekNtT013NnBMT2NWdWVzVlEyd0kyVkI1WklHTmJzQ2xST09NOTdzSjV5UVVKMmhGQUhfZVlMcURaemZkeWxweXFDS0N4WFJPYTdRUGlzbjk2N0tlYzFncTRXU0RpYndWUE12RS1kYUthYmZ0ajBrbUNIOVNZY0…
Group Iv Gp Lp Column Buys 89,200 Shares of Eikon Therapeutics (NASDAQ:EIKN) Stock - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOUmdFNDhERnVIUHctZVp4RENOeG9jbW1FQkFjWGpSeDRlLUctVDRDYV9YNERSN3gwRVNKd3Z4M1NnZGNOekFnMGQ1Um5IR2xIc3N0b0s5WW44VjdwNjBIc1lzbHd3TVI4VkZtZUJIQ3lHZlg2UVhFQlJUNUJxRjNEb1VaNHhfTHZ0UVZTWG…
Eikon Therapeutics, Inc. (EIKN) Stock Price, News, Quote & History - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTFB1ZG8zWXNqOWJkZFRUNUNHeHRmMU5DSTZFb2FNQ0h6SlFNWHhyR1h2WFpCVjJmcXBJNFpxRWJFOHRFRm94QmJKdTYzTFBoUQ?oc=5" target="_blank">Eikon Therapeutics, Inc. (EIKN) Stock Price, News, Quote & Hi…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9rTmpWSWdLWUtZcER4ZHdjTDBmY19nR19WYmJhaElxV0ExY2lWTTdiYktwWUstMWs4V2pEam5tM0VDenM3Y0VENTl3RFlrZ3VH?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
A Bristol Myers Squibb research leader joins Eikon as science chief - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNVjdRbjZuLVVtUmc2czdMcE1fR2hiY0dPWWpPQ3RoRjM1RW9XRncycjRDZDVuOG9QRFlwdDlUMzgyNjNlbHk4dXdObEZWZnZFdU5ZYk5SbGtVdF8zTE9rdVUtZGpsOGFNVGJXb09yUkwxZlcwQnBOZGF2ZTVaazRDZ21vYzBWemw3aFRRal…
EIKN — Frequently Asked Questions
What is the current share price of Eikon Therapeutics, Inc. (EIKN)?
As of 2026-09-19 21:16 PDT, Eikon Therapeutics, Inc. (EIKN) trades at $10.71 on NasdaqGS. Its 52-week range is $8.36 to $16.26.
What is the market capitalisation of EIKN?
Eikon Therapeutics, Inc. (EIKN) has a market capitalisation of $580.11M on NasdaqGS.
What is the P/E ratio of EIKN?
EIKN trades at a trailing price-to-earnings (P/E) ratio of -1.80. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.25.
Is EIKN a good stock to buy?
This page provides a data-driven analysis of Eikon Therapeutics, Inc. (EIKN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.